| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/MCB.17.9.5612 |
| P8608 | Fatcat ID | release_zsitpzqombcs5fbup5elj6p6pu |
| P932 | PMC publication ID | 232409 |
| P698 | PubMed publication ID | 9271436 |
| P2093 | author name string | B W Futscher | |
| G S Watts | |||
| R O Pieper | |||
| W S Dalton | |||
| J F Costello | |||
| Y M Peng | |||
| P2860 | cites work | Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine | Q24336908 |
| High sensitivity mapping of methylated cytosines | Q24630600 | ||
| CpG islands in vertebrate genomes | Q27861045 | ||
| Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents | Q33689518 | ||
| Chromatin structure of transcriptionally competent and repressed genes | Q33923306 | ||
| Repression of genes by DNA methylation depends on CpG density and promoter strength: evidence for involvement of a methyl-CpG binding protein | Q33937316 | ||
| Identification of a 59 bp enhancer located at the first exon/intron boundary of the human O6-methylguanine DNA methyltransferase gene | Q34892501 | ||
| Characterization of the promoter region of the human O6-methylguanine-DNA methyltransferase gene | Q35792879 | ||
| CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2 | Q35848528 | ||
| Methylation-Related Chromatin Structure Is Associated with Exclusion of Transcription Factors from and Suppressed Expression of the O-6-Methylguanine DNA Methyltransferase Gene in Human Glioma Cell Lines | Q36666835 | ||
| The repressor MDBP-2 is a member of the histone H1 family that binds preferentially in vitro and in vivo to methylated nonspecific DNA sequences | Q37241962 | ||
| Lack of the DNA repair protein O6-methylguanine-DNA methyltransferase in histologically normal brain adjacent to primary human brain tumors | Q37476708 | ||
| Nucleosomes: regulators of transcription | Q37793913 | ||
| Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents | Q37952773 | ||
| CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation | Q38344762 | ||
| Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter | Q38346589 | ||
| Transcription: in tune with the histones | Q38483205 | ||
| Structure, Function, and Inhibition of O6-Alkylguanine-DNA Alkyltransferase | Q40473972 | ||
| The methylation status of the gene for O6-methylguanine-DNA methyltransferase in human Mer+ and Mer- cells | Q41318524 | ||
| Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells | Q41460436 | ||
| Epigenetic silencing of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in Mex- human cells | Q41601050 | ||
| Collateral sensitivity to nitrosoureas in multidrug-resistant cells selected with verapamil | Q41603062 | ||
| DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells | Q41614931 | ||
| Comparison of O-6-methylguanine DNA methyltransferase (MGMT) mRNA levels in Mer+ and Mer- human tumor cell lines containing the MGMT gene by the polymerase chain reaction technique | Q41749242 | ||
| Methylation of CpG island transcription factor binding sites is unnecessary for aberrant silencing of the human MGMT gene | Q42632071 | ||
| O6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary | Q48672550 | ||
| Inter- and intracellular heterogeneity of O6-alkylguanine-DNA alkyltransferase expression in human brain tumors: possible significance in nitrosourea therapy | Q49044390 | ||
| Expression of O6-methylguanine-DNA methyltransferase in malignant human glioma cell lines. | Q53496348 | ||
| Response of cultured human cell lines from rhabdomyosarcoma xenografts to treatment with chloroethylnitrosoureas. | Q54359883 | ||
| Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains | Q59085307 | ||
| Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant human cancer cells | Q69319935 | ||
| Measurement of O6-alkylguanine-DNA alkyltransferase activity in human cells and tumor tissues by restriction endonuclease inhibition | Q69811351 | ||
| Histone H1-mediated inhibition of transcription initiation of methylated templates in vitro | Q70500779 | ||
| In vitro methylation of the human O6-methylguanine-DNA methyltransferase promoter reduces transcription | Q72248693 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | CpG island | Q1138360 |
| gene silencing | Q1431332 | ||
| P304 | page(s) | 5612-5619 | |
| P577 | publication date | 1997-09-01 | |
| P1433 | published in | Molecular and Cellular Biology | Q3319478 |
| P1476 | title | Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene | |
| P478 | volume | 17 |
| Q38715704 | 99mTc-Tetrofosmin Uptake Correlates with the Sensitivity of Glioblastoma Cell Lines to Temozolomide |
| Q39599186 | A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. |
| Q37121158 | A female adnexal tumor of probable Wolffian origin showing positive O-6-methylguanine-DNA methyltransferase methylation. |
| Q34427825 | A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas |
| Q61135431 | A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma |
| Q53357337 | Aberrant methylation and loss of expression of O-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma. |
| Q34000287 | Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide |
| Q77932320 | Activation of human O6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone |
| Q51888776 | Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. |
| Q38317424 | Assessing MGMT methylation status and its current impact on treatment in glioblastoma. |
| Q37316991 | Association between response to primary treatments and MGMT status in glioblastoma |
| Q35855352 | Canadian recommendations for the treatment of glioblastoma multiforme. |
| Q64930362 | Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas. |
| Q57462651 | Combined temozolomide and ionizing radiation induces galectin-1 and galectin-3 expression in a model of human glioma |
| Q55052526 | Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide). |
| Q39728639 | Confluence-induced alterations in CpG island methylation in cultured normal human fibroblasts |
| Q23912842 | Correlation of chromosome damage and promoter methylation status of the DNA repair genes MGMT and hMLH1 in Chinese vinyl chloride monomer (VCM)-exposed workers |
| Q45033014 | Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas |
| Q97419396 | Current status of development of methylation biomarkers for in vitro diagnostic IVD applications |
| Q79357532 | De novo DNA methylation at the CpG island of the zebrafish no tail gene |
| Q43977676 | Deficient expression of O(6)-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma |
| Q87822617 | Deletion of the MGMT gene in familial melanoma |
| Q37798947 | Epigenetic Alterations as Cancer Diagnostic, Prognostic, and Predictive Biomarkers |
| Q33335165 | Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes |
| Q26822513 | Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition |
| Q35079153 | Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme. |
| Q36226129 | Epigenetic silencing of the MGMT gene in cancer. |
| Q37467299 | Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model |
| Q35098419 | Flipping the epigenetic switch |
| Q40601124 | Frequent hypermethylation of 5' flanking region of TIMP-2 gene in cervical cancer |
| Q31019127 | Gene MGMT and oligodendrogliomas. Fundamental data and short review of the literature |
| Q35026407 | Gene silencing in phenomena related to DNA repair |
| Q34288659 | Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer |
| Q35117832 | Genetic alterations of human brain tumors as molecular prognostic factors |
| Q35757144 | Genetic pathways to primary and secondary glioblastoma |
| Q37602543 | Glioblastoma Multiforme Oncogenomics and Signaling Pathways |
| Q33536382 | Human DNA repair systems: an overview |
| Q35029017 | Hypermethylation pathways to colorectal cancer. Implications for prevention and detection |
| Q92453280 | Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma |
| Q37344947 | Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas |
| Q39457448 | Immunohistochemical analysis of O(6)-methylguanine-DNA methyltransferase in human melanoma in comparison with skin squamous cell carcinoma |
| Q36644616 | Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers |
| Q51044072 | Inactivation of O⁶-methyguanine-DNA methyltransferase by promoter hypermethylation: association of epithelial ovarian carcinogenesis in specific histological types. |
| Q28388726 | Inter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair research |
| Q35800791 | Intercellular heterogeneity of expression of the MGMT DNA repair gene in pediatric medulloblastoma |
| Q44299436 | Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma |
| Q43255085 | MGMT as a potential stratification marker in relapsed high-grade glioma of children: the HIT-GBM experience |
| Q54199400 | MGMT gene silencing by promoter hypermethylation in gastric cancer in a high incidence area. |
| Q40293483 | MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma |
| Q38218848 | MGMT testing--the challenges for biomarker-based glioma treatment |
| Q34310201 | MGMT: its role in cancer aetiology and cancer therapeutics |
| Q34378429 | Methylation and colorectal cancer |
| Q28364163 | Methylation matters |
| Q53319447 | Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. |
| Q33915724 | Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens |
| Q39452723 | Methylation of the cyclin A1 promoter correlates with gene silencing in somatic cell lines, while tissue-specific expression of cyclin A1 is methylation independent |
| Q33775531 | Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. |
| Q28579983 | Methylguanine methyltransferase activity deficiency in immature rat mammary epithelial cells parallels increased carcinogenic susceptibility |
| Q38233134 | Molecular prognostic factors in glioblastoma: state of the art and future challenges |
| Q37861732 | Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools |
| Q37261125 | New (alternative) temozolomide regimens for the treatment of glioma |
| Q43128475 | O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma |
| Q24685624 | O(6)-methylguanine methyltransferase in colorectal cancers: detection of mutations, loss of expression, and weak association with G:C>A:T transitions |
| Q26853112 | O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems |
| Q89497366 | O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy |
| Q34561510 | O6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy |
| Q39589960 | O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma |
| Q44532454 | Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression |
| Q48137109 | Prognosis of glioblastoma with faint MGMT methylation-specific PCR product |
| Q38382116 | Prognostic Role of Methylation Status of the MGMT Promoter Determined Quantitatively by Pyrosequencing in Glioblastoma Patients |
| Q33651583 | Prognostic and predictive biomarkers: tools in personalized oncology |
| Q28731328 | Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma |
| Q33958962 | Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest |
| Q79270324 | Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma |
| Q21261312 | Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference |
| Q58766022 | Pyrosequencing Analysis of Promoter Methylation in Meningioma |
| Q41027968 | Repair of cyclobutane pyrimidine dimers in the O6-methylguanine-DNA methyltransferase (MGMT) gene of MGMT proficient and deficient human cell lines and comparison with the repair of other genes and a repressed X-chromosomal locus |
| Q38812898 | Reversing epigenetic mechanisms of drug resistance in solid tumors using targeted microRNA delivery |
| Q40731103 | Role for DNA methylation in the control of cell type specific maspin expression |
| Q39783438 | Role of histone modifications and DNA methylation in the regulation of O6-methylguanine-DNA methyltransferase gene expression in human stomach cancer cells |
| Q33979964 | Role of loss of o⁶-methylguanine dna methyltransferase (MGMT) expression in non-small cell lung carcinomas (NSCLCs): with reference to the relationship with p53 overexpression |
| Q48009133 | Selective variegated methylation of the p15 CpG island in acute myeloid leukemia |
| Q34280188 | Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer |
| Q36530688 | Strategies for discovery and validation of methylated and hydroxymethylated DNA biomarkers |
| Q55332110 | Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature. |
| Q99582351 | The Effects of O6-methyl Guanine DNA-methyl Transferase Promotor Methylation and CpG1, CpG2, CpG3 and CpG4 Methylation on Treatment Response and their Prognostic Significance in Patients with Glioblastoma |
| Q38491783 | The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas |
| Q28391635 | The future role of personalized medicine in the treatment of glioblastoma multiforme |
| Q33921072 | The pathobiology of glioma tumors |
| Q77753619 | The sensitization of cells treated with O6-methylguanine to alkylation damage is affected by the number of O6-methylguanine-DNA methyltransferase molecules escaped from inactivation |
| Q84343065 | The status of MGMT protein expression is a prognostic factor for meningeal hemangiopericytoma: a clinicopathologic and immunohistochemical study of 12 cases at a single institution |
| Q30475852 | Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter |
| Q36734626 | Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. |
| Q83139208 | hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies |
Search more.